PubRank

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer (VENICE)

Clinical Trial ID NCT00519285

PubWeight™ 32.07‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00519285

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 2013 3.45
2 Antibody-based therapeutics to watch in 2011. MAbs 2011 2.00
3 Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2010 1.86
4 Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol 2014 1.75
5 Aflibercept. Clin Cancer Res 2013 1.51
6 Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012 1.20
7 Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J 2013 1.09
8 Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther 2010 1.05
9 Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2009 1.04
10 Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther 2010 1.00
11 VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol 2009 0.99
12 The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013 0.97
13 Targeting angiogenesis for the treatment of prostate cancer. Expert Opin Ther Targets 2012 0.97
14 Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets 2012 0.95
15 Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011 0.93
16 Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol 2012 0.91
17 The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Manag Res 2012 0.88
18 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
19 Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? Cancer Manag Res 2013 0.88
20 Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol 2013 0.87
21 Angiogenesis inhibition in prostate cancer: current uses and future promises. J Oncol 2010 0.87
22 Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother 2010 0.86
23 Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist 2011 0.85
24 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
25 Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012 0.81
26 Research in castration-resistant prostate cancer: what does the future hold? Curr Oncol 2010 0.79
27 Future directions in castrate-resistant prostate cancer therapy. Clin Genitourin Cancer 2010 0.79
28 Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. Br J Cancer 2014 0.77
29 Monoclonal antibodies and Fc fragments for treating solid tumors. Biologics 2012 0.75
Next 100